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Introduction {#jdi12887-sec-0005}
============

Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance resulting in hyperglycemia of variable severity, with onset or first recognition during pregnancy[1](#jdi12887-bib-0001){ref-type="ref"}. GDM is reportedly associated with the risk of various maternal and perinatal complications, such as macrosomia, premature delivery and pre‐eclampsia[2](#jdi12887-bib-0002){ref-type="ref"}, and the onset of type 2 diabetes postpartum[3](#jdi12887-bib-0003){ref-type="ref"}. Additionally, GDM promotes the development of obesity and other metabolic disorders in the offspring of GDM mothers later in life[4](#jdi12887-bib-0004){ref-type="ref"}, [5](#jdi12887-bib-0005){ref-type="ref"}, [6](#jdi12887-bib-0006){ref-type="ref"}. Hence, the developmental origins of health and disease is a concept that states that environmental factors during the fetal and perinatal period affect the onset of some non‐communicable diseases in adulthood[7](#jdi12887-bib-0007){ref-type="ref"}. Prevention of GDM development or strict control of plasma glucose in patients with GDM is considered to be important for both pregnant women and their children[8](#jdi12887-bib-0008){ref-type="ref"}. Given the availability of effective interventions for delaying or preventing GDM onset[9](#jdi12887-bib-0009){ref-type="ref"}, [10](#jdi12887-bib-0010){ref-type="ref"}, earlier identification of individuals at risk is particularly crucial. Biomarkers for prediction are required for an effective prevention of GDM. Valid predictive methods have not been established thus far; however, despite the use of conventional risk factors, such as body mass index (BMI), hemoglobin A1c (HbA1c) might possibly prove to be feasible in the development of a predictive method[11](#jdi12887-bib-0011){ref-type="ref"}. Although some hormones and nutrients associated with glucose metabolism have also been reported as potential markers for GDM prediction[12](#jdi12887-bib-0012){ref-type="ref"}, [13](#jdi12887-bib-0013){ref-type="ref"}, these factors alone are not sufficient to predict GDM. Recently, analytical methods to investigate all of the metabolites in an organism, also known as the metabolome, have been established. This method allows for the simultaneous analysis of various metabolites[14](#jdi12887-bib-0014){ref-type="ref"}. Recent studies have reported early detection or prediction of diabetes or impaired glucose metabolism using metabolomic analysis[15](#jdi12887-bib-0015){ref-type="ref"}, [16](#jdi12887-bib-0016){ref-type="ref"}. GDM has been one of the targets of this analytical method. Several studies using a metabolomic approach reported that various metabolites might have the potential to predict the subsequent development of GDM in European, USA or Chinese populations[17](#jdi12887-bib-0017){ref-type="ref"}, [18](#jdi12887-bib-0018){ref-type="ref"}, [19](#jdi12887-bib-0019){ref-type="ref"}, [20](#jdi12887-bib-0020){ref-type="ref"}, [21](#jdi12887-bib-0021){ref-type="ref"}, [22](#jdi12887-bib-0022){ref-type="ref"}, [23](#jdi12887-bib-0023){ref-type="ref"}. Metabolomic profiles are affected by ethnicity[24](#jdi12887-bib-0024){ref-type="ref"}; thus, metabolomic analysis for the Japanese population should be carried out. In the present study, we aimed to explore the novel predictive factors for GDM using the metabolomic analysis of serum and urine from pregnant Japanese women in their first or early second trimester.

Methods {#jdi12887-sec-0006}
=======

Design {#jdi12887-sec-0007}
------

This was a case--control study within a cohort of participants enrolled in the Japan Environment and Children\'s Study (JECS) at the Center of Chiba Unit.

Participants {#jdi12887-sec-0008}
------------

JECS is a nationwide, ongoing cohort study that is planned and implemented to elucidate the influences of environmental factors in the fetus through childhood on children\'s development and health. Pregnant women were recruited for 3 years (2011--2014), and women who agreed to participate were enrolled before delivery. The study design of JECS has been described in detail elsewhere[25](#jdi12887-bib-0025){ref-type="ref"}. Various environmental factors were assessed, and biomaterials, such as maternal blood and urine, were collected[25](#jdi12887-bib-0025){ref-type="ref"}, [26](#jdi12887-bib-0026){ref-type="ref"}. The blood and urine samples obtained randomly at the first visit after enrollment were analyzed in the present study. Blood samples were centrifuged and divided into serum. Serum and urine samples were frozen and stored at −20°C until analysis.

Participants with GDM were defined as those with GDM reported in their medical records at the time of delivery[27](#jdi12887-bib-0027){ref-type="ref"}, and without a past history or diagnosis of GDM reported by the first questionnaires carried out at the beginning of pregnancy (prior to diagnosis of GDM: p‐GDM group). We then selected the same number of participants without a history or diagnosis of GDM who were matched to the cases based on age, BMI and parity for the control group at random. In Japan, GDM screening is recommended using the following stepwise methods for almost all pregnant women. Random blood glucose levels are measured at an early stage of pregnancy. Between 24 and 28 gestational weeks, pregnant women are given a 50‐g glucose challenge test (cut‐off value ≥140 mg/dL), or random blood glucose levels are measured (cut‐off value ≥100 mg/dL). All women with positive screening test results are administered a 75‐g oral glucose tolerance test for GDM diagnosis[28](#jdi12887-bib-0028){ref-type="ref"}.

The present study was carried out according to the Declaration of Helsinki, and the study protocol was approved by the Biomedical Research Ethics Committee of the Graduate School of Medicine, Chiba University, Chiba, Japan. Additionally, written informed consent was obtained from the enrolled participants.

Metabolomic analysis by hydrophilic interaction chromatography tandem mass spectrometry {#jdi12887-sec-0009}
---------------------------------------------------------------------------------------

Metabolomic analysis was carried out as previously described[29](#jdi12887-bib-0029){ref-type="ref"}, [30](#jdi12887-bib-0030){ref-type="ref"}. Serum and urine levels of 42 and 263 metabolites, respectively, found to be detectable under our storage conditions (−20°C) were pre‐treated[31](#jdi12887-bib-0031){ref-type="ref"} and analyzed using hydrophilic interaction chromatography tandem mass spectrometry methods as previously reported[31](#jdi12887-bib-0031){ref-type="ref"}, [32](#jdi12887-bib-0032){ref-type="ref"}. Briefly, after centrifugation at 14,000 *g* for 10 min, 40 μL of sample and 60 μL of methanol containing the internal standards (1 nmol/L lidocaine and N,N‐diethyl‐2‐phenylacetamide for positive ion mode, and D‐camphor‐10‐sulfonic acid for negative ion mode) to adjust for sample loss during the pretreatment procedure were pipetted onto Amicon^®^ Ultra‐0.5 3K filter columns (Merck Millipore, Tokyo, Japan). The columns were centrifuged at 14,000 *g* for 1 h, and the filtrates were analyzed using Prominence UFLC (Shimadzu, Kyoto, Japan) and QTRAP 4500 systems (AB SCIEX, Tokyo, Japan). Samples were delivered to mass spectrometry through hydrophilic interaction chromatography using a 3.5‐μm XBridge BEH Amide column (Waters, Tokyo, Japan), 4.6 mm (internal diameter) × 100 mm, at a flow rate of 350 μL/min. In the present study, we analyzed the target metabolome using a gradient of mobile phase A (20 mmol/L ammonium hydroxide/20 mmol/L ammonium acetate \[pH 9.0\] in ultrapure water : acetonitrile \[95:5\]) and mobile phase B (high‐performance liquid chromatography‐grade acetonitrile). Peak areas from the total ion current for each metabolite selected reaction monitoring transition were integrated using MultiQuant v3.0 software (AB SCIEX). The peak integration settings used were as described by Yuan *et al*.[31](#jdi12887-bib-0031){ref-type="ref"}. Urine metabolites were corrected using the peak area of creatinine in each sample.

Statistical analysis {#jdi12887-sec-0010}
--------------------

Data are presented as mean ± standard deviation or median (interquartile range). Differences in the measurement values between p‐GDM and control groups were evaluated by unpaired *t*‐tests, Mann--Whitney tests or Fisher\'s exact tests according to their distribution. Orthogonal projections to latent structures discriminant analysis (OPLS‐DA) were carried out to investigate metabolome profiles of different groups using R package ropls[33](#jdi12887-bib-0033){ref-type="ref"} in Microsoft R open 3.3.0 (R Core Team, 2016, R Core Team R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria). Metabolites with a variable importance in projection value \>1.5 were identified as potential markers. The statistical significance and validity of the OPLS‐DA model were calculated using a permutation test (number of permutations = 1,000)[34](#jdi12887-bib-0034){ref-type="ref"}. The sensitivity and specificity of each metabolite was assessed using the receiver operating characteristic (ROC) curve and respective area under the ROC curve (AUC~ROC~) carried out using R package ROCR[35](#jdi12887-bib-0035){ref-type="ref"}. It has been previously reported that several metabolites can be affected by gestational age[36](#jdi12887-bib-0036){ref-type="ref"}. Thus, we carried out comparisons and ROC analyses using the data obtained before 16 weeks‐of‐gestational age (serum: p‐GDM *n* = 32, controls *n* = 44; urine: p‐GDM *n* = 11, controls *n* = 13).

To identify pathways that changed in the p‐GDM group, we used an enrichment analysis using MBRole 2 (Computational Systems Biology Group, National Center for Biotechnology \[CNB‐CSIC\], Madrid, Spain)[37](#jdi12887-bib-0037){ref-type="ref"}. In this study, we used a false discovery rate value[38](#jdi12887-bib-0038){ref-type="ref"} of \<0.05 as the threshold to judge the significantly enriched metabolic pathways of submitted metabolites using the Kyoto Encyclopedia of Genes and Genomes ID of potential biomarkers[39](#jdi12887-bib-0039){ref-type="ref"}.

Results {#jdi12887-sec-0011}
=======

From 2011 to 2014, approximately 6,000 participants were recruited at the Chiba Unit Center, of which 167 developed GDM based on medical record reviews used to match the p‐GDM group. Serum samples were available from 121 participants in the p‐GDM group for metabolomic analysis. We then selected 121 participants for the control group. The characteristics of the p‐GDM and control groups are shown in Table [1](#jdi12887-tbl-0001){ref-type="table"}. Age, pre‐pregnancy weight, height, pre‐pregnancy BMI and ratio of primipara did not significantly differ between the groups. HbA1c values and gestational age in weeks at the time of sample collection in the p‐GDM group were significantly higher than in the control group. The urine samples of 67 (p‐GDM: 36, control: 31) of 242 participants were also analyzed.

###### 

Participant characteristics

  Characteristics                                  p‐GDM         Control       *P*‐value
  ------------------------------------------------ ------------- ------------- -----------
  Age (years)                                      32.0 (5.0)    31.9 (4.8)    0.90
  Pre‐pregnant weight (kg)                         57.5 (12.8)   57.8 (13.2)   0.82
  Height (cm)                                      158.4 (5.5)   158.7 (5.3)   0.58
  Pre‐pregnancy BMI (kg/m^2^)                      22.4 (5.4)    22.9 (4.8)    0.49
  Gestational weight gain (kg)                     8.6 (5.1)     9.3 (4.7)     0.24
  Parity                                           0.81 (1.06)   0.86 (0.91)   0.68
  Gestational weeks at sample collection (weeks)   18.6 (3.8)    17.3 (3.5)    \<0.01
  HbA1c                                            5.15 (0.41)   5.03 (0.30)   0.01

Values are shown as mean (standard deviation). BMI, body mass index; HbA1c, hemoglobin A1c; p‐GDM, prior to diagnosis of gestational diabetes mellitus.

John Wiley & Sons, Ltd

To identify metabolic differences between the p‐GDM and control groups, we quantified serum and urine metabolites during early pregnancy. Using hydrophilic interaction chromatography tandem mass spectrometry, 32 of the 187 and 42 of the 263 targeted metabolites in serum and urine were detected in \>50% of analyzed samples, respectively.

We carried out OPLS‐DA to generate discrimination models (Figure [S1](#jdi12887-sup-0001){ref-type="supplementary-material"}). In serum, the predictive ability of R2X, R2Y and Q2 was 0.388, 0.492 and 0.45, respectively, whereas in urine, the predictive ability of R2X, R2Y and Q2 was 0.454, 0.674 and 0.483, respectively. The original model did not belong to the population of 1,000 randomly permuted models (for serum and urine, R2Y and Q2: *P* \< 0.001), showing the significance of the fitness and prediction ability attached with the original OPLS‐DA model. Variable importance in projection scores was calculated for each metabolite based on its contribution to statistical discrimination. In total, 3 and 20 metabolites were found to meet the selection criteria (variable importance in projection \>1.5) in serum (Table [2](#jdi12887-tbl-0002){ref-type="table"}) and urine (Table [3](#jdi12887-tbl-0003){ref-type="table"}), respectively, and were therefore subjected to further evaluation.

###### 

Metabolite markers identified in serum

                                    VIP    Coefficient
  --------------------------------- ------ -------------
  Glutamine                         2.39   −0.1866
  Pyrophosphate                     2.34   −0.1900
  Octulose‐1,8‐bisphosphate (OBP)   2.24   −0.1366

Metabolites with variable importance in projection (VIP) of \>1.5 are shown.

John Wiley & Sons, Ltd

###### 

Metabolite markers identified in urine

                                VIP    Coefficient
  ----------------------------- ------ -------------
  Shikimate‐3‐phosphate         2.91   0.0510
  Ethanolamine                  2.59   −0.0620
  1,3‐Diphopshateglycerate      2.36   0.0625
  Leucine‐isoleucine            2.04   −0.0413
  p‐Hydroxybenzoate             1.96   0.0309
  Hydroxyphenylpyruvate         1.87   −0.0326
  N‐acetyl‐L‐alanine            1.83   0.0420
  Hydroxyproline                1.83   −0.0353
  Octulose‐monophosphate        1.76   −0.0261
  N‐acetyl‐glucosamine          1.74   −0.0327
  Shikimate                     1.73   −0.0273
  Cellobiose                    1.71   0.0337
  Threonine                     1.70   −0.0354
  Methylcysteine                1.70   −0.0331
  Methionine sulfoxide          1.69   −0.0350
  Urea                          1.66   −0.0311
  Deoxyribose‐phosphate         1.65   −0.0305
  Methionine                    1.61   −0.0379
  Acadesine                     1.54   −0.0324
  D‐sedoheptulose‐7‐phosphate   1.52   −0.0299

Metabolites with variable importance in projection (VIP) of \>1.5 are shown.

John Wiley & Sons, Ltd

In serum, glutamine (*P* \< 0.001), pyrophosphate (*P* \< 0.001) and octulose‐1,8‐bisphosphate (*P *\< 0.001) significantly differed between the p‐GDM and control groups. Shikimate‐3‐phosphate (*P* \< 0.001), ethanolamine (*P* \< 0.001), 1,3‐diphosphoglycerate (*P *\< 0.001), N‐acetyl‐L‐alanine (*P* \< 0.001) and methionine (*P* \< 0.001) in urine were also significantly different between the groups (Table [4](#jdi12887-tbl-0004){ref-type="table"}). In the p‐GDM group, one serum sample had been obtained during the third trimester, whereas all others had been obtained during the first or second trimester. We carried out the same analyses excluding the serum sample obtained during the third trimester. The results were comparable with those described above, and therefore we carried out the subsequent analyses without this serum sample.

###### 

Area under the receiver operating characteristic curve for metabolite markers, and differences in the serum and urine metabolite markers stratified by pre‐gestational diabetes vs control groups

                              p‐GDM                     Control                 *P*‐value   FDR        AUC
  --------------------------- ------------------------- ----------------------- ----------- ---------- -------
  Serum                                                                                                
  Glutamine                   0.15 (0.098--0.21)        0.29 (0.25--0.35)       3.74E‐16    1.57E‐14   0.804
  Pyrophosphate               0.0071 (0.00--0.043)      0.092 (0.0054--0.18)    9.03E‐10    3.70E‐08   0.725
  Octulose‐1,8‐bisphosphate   0.15 (0.035--0.23)        0.24 (0.15--0.36)       4.25E‐07    1.70E‐05   0.689
  Urine                                                                                                
  Shikimate‐3‐phosphate       0.047 (0.032--0.062)      0.032 (0.023--0.040)    1.13E‐04    2.94E‐02   0.768
  Ethanolamine                0.039 (0.028--0.053)      0.070 (0.055--0.096)    2.47E‐06    6.47E‐04   0.821
  1,3‐Diphosphoglycerate      0.037 (0.023--0.053)      0.015 (0.011--0.022)    2.38E‐07    6.27E‐05   0.848
  N‐acetyl‐L‐alanine          0.071 (0.054--0.11)       0.046 (0.027--0.073)    8.00E‐04    2.08E‐01   0.735
  Methionine                  0.0064 (0.0041--0.0098)   0.013 (0.0072--0.017)   2.29E‐03    5.93E‐01   0.718

Data are presented as median (interquartile range). AUC, area under the receiver operating characteristic curve; p‐GDM, prior to diagnosis of gestational diabetes.

John Wiley & Sons, Ltd

Among these metabolites, glutamine in serum and ethanolamine and 1,3‐diphosphoglycerate in urine showed \>0.80 AUC~ROC~ values in the prediction model for discrimination between the p‐GDM and control groups (Table [4](#jdi12887-tbl-0004){ref-type="table"}). These results suggest that glutamine in serum, and ethanolamine and 1,3‐diphosphoglycerate in urine are candidate predictive markers for GDM (Figure [S2](#jdi12887-sup-0002){ref-type="supplementary-material"}). In contrast, the AUC~ROC~ value for HbA1c was 0.58.

Using the data from before 16 weeks‐of‐gestational age, we compared the aforementioned three metabolites between the groups. The levels of these three metabolites were significantly different between the groups (data not shown). The AUC~ROC~ values of glutamine in serum, and ethanolamine and 1,3‐diphosphoglycerate in urine were 0.81, 0.92 and 0.78, respectively.

Enrichment analysis showed that the metabolites contributing to discrimination in urine were related to seven pathways (Table [5](#jdi12887-tbl-0005){ref-type="table"}). These pathways are associated with amino acid metabolism and the pentose phosphate pathway.

###### 

Altered metabolites identified as potential markers in urine using enrichment analysis

  Annotation                                            *P*‐value   FDR correction   Matching identification
  ----------------------------------------------------- ----------- ---------------- -----------------------------
  Valine, leucine and isoleucine biosynthesis           2.23E‐04    5.13E‐03         C00123 C04236 C00188
  ABC transporters                                      5.36E‐04    6.16E‐03         C00123 C00185 C00188 C00086
  Betaine--homocysteine S‐methyltransferase             4.23E‐04    1.14E‐02         C00155 C00073
  Methionine synthase                                   1.46E‐03    1.97E‐02         C00155 C00073
  Aminoacyl‐tRNA biosynthesis                           4.05E‐03    2.17E‐02         C00123 C00188 C00073
  Phenylalanine, tyrosine and tryptophan biosynthesis   6.14E‐03    2.35E‐02         C03175 C01179
  Pentose phosphate pathway                             8.56E‐03    2.81E‐02         C00673 C05382

FDR, false discovery rate; tRNA, transfer ribonucleic acid.

John Wiley & Sons, Ltd

Discussion {#jdi12887-sec-0012}
==========

In the present study, we found that glutamine in serum, and ethanolamine and 1,3‐diphosphoglycerate in urine might be new predictive metabolites for GDM in Japanese women during early pregnancy using metabolomic analysis.

Gestational diabetes mellitus is reported to be associated with both maternal and fetal adverse outcomes; thus, blood glucose levels must be controlled within an appropriate range to prevent the onset of adverse outcomes. A previous study showed that an intensive therapeutic approach might be useful for this purpose[8](#jdi12887-bib-0008){ref-type="ref"}. Prediction of GDM before its onset is also required, as it allows for the provision of early interventions for susceptible women to prevent GDM.

Several factors have been reported to predict GDM, such as age, pre‐pregnancy BMI, family history of diabetes and history of large‐for‐gestational age infant delivery. As we selected the control group based on age, pre‐pregnancy BMI and parity of p‐GDM group, which are risk factors for GDM, their predictive values could not be evaluated in the present study. However, we examined the predictive value of HbA1c. Although maternal HbA1c level in early pregnancy significantly differed between the groups, the predictive ability of HbA1c was not sufficient in our cohort, as suggested by its low AUC~ROC~ value. It was reported that HbA1c within the normal range alone might not be sufficient to predict GDM[12](#jdi12887-bib-0012){ref-type="ref"}. Here, most of the participants showed HbA1c \<5.7%, which might be the reason why HbA1c did not show sufficient predictive ability. However, several studies have reported that HbA1c was useful in predicting subsequent GDM or to exclude women who are at low risk for GDM[40](#jdi12887-bib-0040){ref-type="ref"}, [41](#jdi12887-bib-0041){ref-type="ref"}, [42](#jdi12887-bib-0042){ref-type="ref"}. The inconsistency in the results might have been due to the difference in study population or other risk factors. Larger cohort studies are required to elucidate the ability of HbA1c to predict GDM. Our cohort had no family history of diabetes, which is an important predictor of GDM[11](#jdi12887-bib-0011){ref-type="ref"}. Several studies have shown that the alterations of the metabolites are useful in predicting GDM, especially when added to clinical findings, such as family history[23](#jdi12887-bib-0023){ref-type="ref"}, [43](#jdi12887-bib-0043){ref-type="ref"}. The present results should be validated using other cohorts in combination with these clinical findings.

The present data suggest that glutamine in serum, and ethanolamine and 1,3‐diphosphoglycerate in urine are potential predictive markers, as shown by their AUC~ROC~ values. Glutamine is reported to increase insulin secretion and suppress β‐cell apoptosis in diabetic rats[44](#jdi12887-bib-0044){ref-type="ref"}. Conversely, glutamine stimulated α‐cell proliferation through mammalian target of rapamycin signal[45](#jdi12887-bib-0045){ref-type="ref"}. Meta‐analysis of metabolomics data showed that blood glutamine was inversely associated with the risk of type 2 diabetes development[46](#jdi12887-bib-0046){ref-type="ref"}. Glutamine is considered to play an important role in glucose metabolism in p‐GDM pregnant women. Ethanolamine is a metabolite of glycerophospholipid metabolism. Glycerophospholipid metabolism is reportedly associated with GDM or pre‐diabetes[17](#jdi12887-bib-0017){ref-type="ref"}, [47](#jdi12887-bib-0047){ref-type="ref"}. However, the role of ethanolamine itself in glucose metabolism still remains unclear and warrants further studies. 1,3‐Diphosphoglycerate is a metabolite of glycolysis and gluconeogenesis. Alteration of urinary 1,3‐diphosphoglycerate might reflect the changes in glycolytic or gluconeogenic pathways of patients in the p‐GDM state. The precise mechanism of alteration of these metabolites has not yet been clarified; hence, further studies are required.

Several amino acids are reportedly associated with the p‐GDM state, such as glutamate and serine[48](#jdi12887-bib-0048){ref-type="ref"}. The present results showed this trend for glutamate, although its contribution to prediction was unremarkable. Urinary choline was reported to be one of the predictor candidates for GDM[48](#jdi12887-bib-0048){ref-type="ref"}, [49](#jdi12887-bib-0049){ref-type="ref"}, [50](#jdi12887-bib-0050){ref-type="ref"}. In our study, choline did not show an ability to predict GDM. Metabolites that were not detected to have a positive predictive ability for GDM in the present study have also been reported to predict GDM in the previous literature[17](#jdi12887-bib-0017){ref-type="ref"}. Because there are several differences between the results from previous studies and the present results, such as the timing of sample collection, analytical methods or ethnicity, we could not detect other metabolites in this study. Bentley‐Lewis *et al*.[22](#jdi12887-bib-0022){ref-type="ref"} reported that metabolomic profiles were different among USA, Chinese and Japanese people. They explained that these differences might be caused by dietary habits or gut microbiome[22](#jdi12887-bib-0022){ref-type="ref"}. It is useful to analyze the metabolomic profiles of individuals from each ethnic group. In addition, GDM is thought to have a common pathogenic pathway. Therefore, we need to study GDM prediction using metabolomic analysis from the point of view of the ethnic‐specific characteristics and common pathogenic mechanism.

The present data showed that maternal urine had more metabolites that were associated with subsequent GDM than serum. Given these findings and that urine collection is less invasive than blood collection, urine might be a suitable biological material obtained from pregnant women in their first to early second trimester to examine the risk of subsequent GDM.

Enrichment analysis showed that amino acid metabolism and the pentose phosphate pathway were related to p‐GDM status. In several studies in which metabolomic analysis has been applied for the prediction of GDM, metabolites in amino acid metabolism were possible biomarkers[17](#jdi12887-bib-0017){ref-type="ref"}, [18](#jdi12887-bib-0018){ref-type="ref"}, [19](#jdi12887-bib-0019){ref-type="ref"}, [20](#jdi12887-bib-0020){ref-type="ref"}, [21](#jdi12887-bib-0021){ref-type="ref"}, [22](#jdi12887-bib-0022){ref-type="ref"}, [23](#jdi12887-bib-0023){ref-type="ref"}. The alteration of amino acid metabolism is reportedly associated with type 2 diabetes and the development of diabetes in the future[15](#jdi12887-bib-0015){ref-type="ref"}, [16](#jdi12887-bib-0016){ref-type="ref"}. Amino acids activate the mammalian target of rapamycin signal pathway, which is involved in insulin receptor signaling and glucose metabolism[51](#jdi12887-bib-0051){ref-type="ref"}. In the present study, several amino acid metabolic pathways were associated with subsequent GDM. These data suggest that the alterations in amino acid metabolism were associated with p‐GDM and can resemble type 2 diabetes or a pre‐diabetes status.

Recently, the pentose phosphate pathway has been reportedly associated with adiposity, a higher glycemic phenotype[52](#jdi12887-bib-0052){ref-type="ref"} and diabetes complications[48](#jdi12887-bib-0048){ref-type="ref"}. In studies involving a cohort of university students, it was shown using glucose tolerance tests that alterations in the pentose phosphate pathway were associated with glucose metabolism[30](#jdi12887-bib-0030){ref-type="ref"}, [53](#jdi12887-bib-0053){ref-type="ref"}. The pentose phosphate pathway is associated with purine metabolism, which is reportedly associated with GDM[18](#jdi12887-bib-0018){ref-type="ref"}, [22](#jdi12887-bib-0022){ref-type="ref"}. The key enzyme of pentose phosphate pathway, glucose‐6‐phosphate dehydrogenase, has been reported to be associated with insulin resistance[54](#jdi12887-bib-0054){ref-type="ref"}. Increased expression of glucose‐6‐phosphate dehydrogenase promotes β‐cell dysfunction and apoptosis[55](#jdi12887-bib-0055){ref-type="ref"}. Conversely, high glucose levels can activate the pentose phosphate pathway[56](#jdi12887-bib-0056){ref-type="ref"}. These data and the present findings show that the pentose phosphate pathway or purine metabolism play an important role in impaired glucose metabolism including p‐GDM status. Additionally, alteration of the pentose phosphate pathway might be caused by altered glucose metabolism reflecting a p‐GDM state.

The present study was subject to several limitations. The JECS is a multi‐region, multi‐facility cohort study; thus, we could not review the accuracy of the diagnostic process or oral glucose tolerance test results for all enrolled participants. Hence, the diagnostic criteria for GDM might not have been consistently used[27](#jdi12887-bib-0027){ref-type="ref"}. We did not obtain the history of the study participants regarding whether delivery of a large‐for‐gestational age neonate occurred. We sampled blood and urine randomly. Therefore, we could not determine the accurate relationship between the metabolites and meals. Metabolic status is considered to be affected by diet[57](#jdi12887-bib-0057){ref-type="ref"}; however, we did not make adjustments for diet in any of our analyses. Serum and urine were stored at −20°C; therefore, it is possible that some metabolite profiles were altered, although the stability of urine samples at −20°C has been previously reported[58](#jdi12887-bib-0058){ref-type="ref"}. Consequently, the present data might not reflect the precise metabolic status of the participants.

In conclusion, the present study identified metabolites in randomly obtained serum and urine samples that distinguish the p‐GDM group from the control group during early pregnancy. Glutamine in serum, as well as ethanolamine and 1,3‐diphosphoglycerate in urine, are possible predictive markers of subsequent GDM in Japanese women. Amino acid metabolism and the pentose phosphate pathway could be key metabolic pathways associated with p‐GDM status. These findings might provide new insights into the prediction of GDM. Further studies are required to elucidate the efficacy of these metabolites as predictive markers at an earlier gestational age in other cohorts.
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###### 

**Figure S1 ¦** Score plots of orthogonal projections to latent structures discriminant analysis model from serum and urine.
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Click here for additional data file.

###### 

**Figure S2 ¦** Receiver operating characteristic curves of metabolites in serum and urine.

###### 

Click here for additional data file.
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